Translational Therapeutics Accelerator Pilot Award
This service is provided by the Translational Therapeutics Accelerator (TRx) Resource.
The annual Translational Therapeutics Accelerator (TRx) Pilot Award is designed to provide investigators with the resources to position their therapeutic discoveries for future commercial value. The funding is awarded to therapeutic projects with the potential to impact human health. Awardees are expected to develop a commercially relevant product profile and meet targeted 12-month milestones.
The application process begins with a pre-proposal. Pre-proposals will be reviewed for eligibility and selected projects will go through the required Life Science Accelerator Boot Camp, led by experts in the field. After attending the LSA Boot Camp, the selected projects will then be eligible to submit a full pilot award application.
Areas of Interest
Therapeutic projects in any stage of development, with a valid target and a translational/commercialization trajectory are encouraged to apply. Special consideration may be given to the development of therapeutics for rare diseases originating from precision medicine efforts and to proposals with a focus on opioid research and novel therapeutics for pain. Therapeutic strategies including small molecules, biologics, novel delivery approaches, gene therapy, and cell therapeutics will be considered.
See a list of current and past Translational Therapeutics Accelerator Pilot Award recipients.
- Pre-proposal applicants must be full-time Columbia University faculty.
- Applicants are encouraged to apply as teams which include at least one clinician and one basic scientist.
- To be eligible for the full pilot award, at least one member of the applicant team (including students and post-docs) must have attended the Life Sciences Accelerator Boot Camp.
The application cycle for 2020-21 is now closed. Applications will be accepted again in Fall 2021.
Cite it, Submit it, Share it!
If your research has benefited from one or more Irving Institute resources, please remember to: